Investigation of IRAK4 Inhibition to Mitigate the Impact of COVID-19 in Severe SARS-CoV-2 (I-RAMIC)
Latest Information Update: 28 Oct 2021
At a glance
- Drugs Zimlovisertib (Primary) ; Zimlovisertib (Primary)
- Indications COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms I-RAMIC
- 18 Oct 2021 Status changed from active, no longer recruiting to discontinued (Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment).
- 13 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 18 May 2021 Planned End Date changed from 31 Mar 2021 to 31 Dec 2021.